New flu vaccine shows promise in south korean trial
NCT ID NCT05144945
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tested a new recombinant flu vaccine (RIV4) against a standard inactivated flu vaccine (IIV4) in 301 healthy adults aged 18 and older in South Korea. The study measured antibody levels and safety over 29 days. The goal was to see if the new vaccine triggers a stronger immune response with similar safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Quadrivalent Recombinant Influenza Vaccine (RIV4)
What this could lead to
If successful, this could offer a more effective or equally protective flu vaccine option for adults, especially those 50 and older.
What could go wrong
This is a completed phase 3 trial, but results may not apply to all populations or flu seasons. The new vaccine may not prove superior to the existing one.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA (HEALTHY VOLUNTEERS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :4100001
Seoul, Seoul-teukbyeolsi, 152-703, South Korea
-
Investigational Site Number :4100002
Seoul, 07441, South Korea
-
Investigational Site Number :4100003
Ansan-si, Gyeonggi-do, 15355, South Korea